From Reference Values to Clinical Impact: Monocyte-to-HDL Ratio (MHR) and Its Association with Inflammation and Mortality

World Allergy Organization Journal 2026 Open access

Read full text
Authors: Ahmed Arabi, Alaa Abdelhamid, Dima Nasrallah, Yaman Al-Haneedi, Deemah Assami, Raneem Alnassif Alsheikh, Susu M. Zughaier
DOI: 10.1016/j.waojou.2026.101318
Cited by: 1

Abstract

Traditional inflammatory biomarkers fail to capture the interplay between inflammation and lipid metabolism, key drivers of disease progression, especially in the context of cardiovascular-kidney-metabolic health [1]. The novel Monocyte-to-HDL Ratio (MHR) biomarker reflects monocyte-driven inflammation and HDL’s anti-inflammatory properties [2]. MHR's reference ranges and prognostic utility remain undefined. This study establishes normal MHR reference ranges and examines its association with various inflammatory diseases and associated mortality, including cardiovascular diseases (CVD), respiratory diseases (RD), kidney diseases (KD), diabetes mellitus (DM), and cancers.

Fields of Study & Subjects

Inflammatory Biomarkers in Disease Prognosis Adipokines Inflammation and Metabolic Diseases Immune cells in cancer

Publication details

Journal / source
World Allergy Organization Journal
Publisher
Elsevier BV
Volume
19
Issue
2
Pages
101318–101318
Publication date
1 February 2026
Language
EN